Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Werewolf Therapeutics Inc (NQ: HOWL ) 2.440 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Werewolf Therapeutics Inc < Previous 1 2 Next > Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting Today 9:02 EST From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Today 9:00 EST From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases October 31, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting October 04, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma June 25, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors June 01, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference May 30, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting May 23, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 03, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting April 23, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting April 05, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting April 04, 2024 PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel... From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference March 06, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 March 05, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook January 08, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors January 04, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference November 22, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 14, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting November 03, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting October 31, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting September 27, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 September 11, 2023 Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Participate in Upcoming Investor Conferences September 05, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present at the Jefferies Healthcare Conference June 01, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
